NCT05312294View on ClinicalTrials.gov

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

654

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

September 3, 2021

Study Completion Date

November 15, 2021

Conditions
InfluenzaFlu, Human
Interventions
BIOLOGICAL

Flu-M [inactivated split influenza vaccine] without preservative

Solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Flu-M [inactivated split influenza vaccine] with preservative

Solution for intramuscular injection, 0.5 ml

Trial Locations (8)

Unknown

"State Autonomous Health Institution Engels City Clinical Hospital No1", Engel's

"Limited Liability Company Professorskaya Clinica", Perm

"Limited Liability Company Clinika Zvezdnaya", Saint Petersburg

"Limited Liability Company MEDICINSKAYA CLINIKA", Saint Petersburg

"Limited Liability Company PeterClinic", Saint Petersburg

"Limited Liability Company Scientific Research Center Eco-Safety", Saint Petersburg

"Saint Petersburg State Budgetary Healthcare Institution State Polyclinic No. 117", Saint Petersburg

"Limited Liability Company Medical Center Diagnostics and Prevention Plus", Yaroslavl

All Listed Sponsors
lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05312294 - Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years | Biotech Hunter | Biotech Hunter